ADVERTORIAL
5 MINUTES WITH ... IAIN DE HAVILLAND
Founder of NADclinic Group, Iain De Havilland discusses evolution of NAD+ therapy and the growing role of personalised longevity medicine in aesthetics.
WHAT FIRST INTRODUCED YOU TO NAD+?
“I first came across NAD+ through its use in addiction and detox medicine. I became convinced that its relevance could extend far beyond the very narrow context in which it was then being used.
“We launched NADclinic in 2016 with a fairly simple belief that the science pertaining to NAD+ therapy deserved a much bigger conversation. The opportunity was never just to build an IV clinic. It was to take something highly specialised, apply proper standards, education and clinical thinking around it, and explore how NAD+ could fit into a much broader model of longevity, resilience and human performance.”
WHAT IS DRIVING THE INTEREST?
“People do not want to wait until something goes wrong. They want to understand their biology earlier, maintain their energy and resilience, recover better and remain physically and cognitively capable for longer.
“NAD+ fits naturally into that conversation because it is fundamental to cellular metabolism and plays an important role in energy production and wider cellular processes. “Aesthetics is experiencing exactly the same evolution. The conversation is moving from simply treating what we can see on the outside towards understanding the biology underneath it.”
WHAT IS NAD’S ROLE IN THE BODY?
“I normally describe NAD+ as part of the body’s cellular energy infrastructure. Every cell depends on it. It plays an essential role in the reactions that allow nutrients to be converted into usable cellular energy, while also participating in pathways involving DNA repair, cellular signalling and stress responses.
“That biological importance is why researchers are studying NAD metabolism across ageing, metabolic health, neurological function, muscle health and other areas. But we also need to distinguish exciting biology from established clinical outcomes. There is strong mechanistic science around NAD+, while human outcome data are still developing and vary depending on the intervention and route of delivery.”
HOW HAS THE NADCLINIC EVOLVED?
“Since launching in 2016 with NAD+, NADclinic Group has expanded into more than 40 countries, working with leading clinicians, medical and aesthetic clinics, hospitality groups, professional sport and wellness organisations, while developing advanced diagnostics, delivery systems and performance medicine platforms.
“The biggest evolution has been philosophical. We have moved from intervention to infrastructure. Products matter, but so do education, manufacturing quality, diagnostics, clinical governance, distribution and the people making the decisions.”
HOW DO YOU ENSURE TREATMENTS ARE GROUNDED IN SCIENTIFIC EVIDENCE?
“Innovation is exciting, but innovation without discipline eventually damages an industry.
“Our approach starts with quality of product, manufacturing standards, sterility where applicable, batch traceability, documentation and appropriate clinical oversight.
“We also try to be very disciplined about language. A promising mechanism is not the same thing as a proven clinical outcome. Animal data are not human data. An interesting biomarker does not automatically translate into a meaningful patient benefit.”
“Longevity has sometimes moved faster commercially than the evidence underneath it. Our philosophy is straightforward: Push innovation hard, but never lower the bar to do it.”
WHAT SHOULD CLINICS CONSIDER BEFORE INTRODUCING NAD+ THERAPIES?
“My first advice would be: do not simply add NAD+ to a treatment menu because patients are asking for it.
“Understand what you are offering and why, starting with appropriate patient assessment, medical history, medications, contraindications and a clear conversation around expectations. It then extends to product provenance, formulation, sterility, storage, administration protocols, clinical training, monitoring and aftercare.
“The practitioner also needs to understand where NAD+ sits within the patient’s wider picture. At NADclinic we increasingly favour a measure first, intervene intelligently, measure again philosophy. The future patient may not see skin, hormones, metabolism, recovery and longevity as completely separate conversations.”
WHAT DO YOU BELIEVE THE NEXT CHAPTER OF NAD+ WILL LOOK LIKE?
“The next chapter is integration. Diagnostics will establish a baseline. AI and longitudinal data will help identify patterns. Clinicians will interpret that information. Nutrition, movement, sleep and strength remain the foundations, while interventions such as NAD+, metabolic medicines, hormonal optimisation, regenerative therapies and more sophisticated peptide strategies sit around them where appropriate. And then we measure again.
“Aesthetics has historically been brilliant at treating the visible expression of ageing. Longevity medicine asks what is happening underneath it.
“I believe the next generation of great aesthetic clinics will increasingly understand both. Not simply helping people look younger, but helping them remain biologically resilient, metabolically healthy and capable for longer.”
This article is sponsored by NAD Clinic